Survivorship and Immune Checkpoint Inhibitors
Findings from a series of long-term survivors with melanoma, renal cell carcinoma and non–small cell lung cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
Consensus on Conceptual Framework for Precision Cancer Medicine in Germany
Collaborative efforts of fourteen comprehensive cancer centres within the German Cancer Aid network
Pregnancy is Safe After Early Breast Cancer in Young Women with Germline BRCA Mutations
Findings provide reassurance about feasibility and safety of future fertility
Assessment of Patients’ Perspective on the Consequences of the COVID-19 Pandemic on Cancer Care
Results from the survey among 5302 cancer patients in the Netherlands
New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines
The errors reported included incorrect use of the needle or syringe, causing the medicine to leak from the syringe, and failure to inject leuprorelin properly
FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
Cedazuridine was investigated in ASTX727-01-B and ASTX727-02 trials
Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy
Promising antitumour activity and acceptable safety profile in patients with HER2-mutated advanced non-small cell lung cancer who had received at least one prior platinum-based chemotherapy
Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative Early Breast Cancer
Results from the BIG 1-98 study
T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic Breast Cancer and Brain Metastases
Results from the KAMILLA exploratory analysis
FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer
Approval is based on findings from the KEYNOTE‑177 study
FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment
Efficacy was investigated in the JAVELIN Bladder 100 trial
EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib
It was intended for the treatment of tenosynovial giant cell tumour